Skip to search boxSkip to navigationSkip to main content

Expression of CYP4A1 in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo

  • Austin M. Guo
    ,
  • Ju Sheng
    ,
  • Gloria M. Scicli
    ,
  • ,
  • Norman L. Lehman
    ,
  • Paul A. Edwards
  • Henry Ford Health System
    ,
  • University of Texas Southwestern Medical Center
    ,
  • Medical College of Wisconsin
    ,
  • Wayne State University
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Exogenous 20-hydroxyeicosatetraenoic acid (20-HETE) increases the growth of human glioma cells in vitro. However, glioma cells in culture show negligible 20-HETE synthesis. We examined whether inducing the expression of a 20-HETE synthase in a human glioma U251 cell line would increase proliferation. U251 cells transfected with CYP4A1 cDNA (termed U251 O) increased the formation of 20-HETE from less than 1 to over 60 pmol/min/mg proteins and increased their proliferation rate by 2-fold (p < 0.01). Compared with control U251, U251 O cells were rounded, smaller, showed a disorganized cytoskeleton, exhibited reduced vinculin staining, and were easily detached from the growing surface. They showed a marked increase in dihydroethidium staining, suggesting increased oxidative stress. The expression of phosphorylated extracellular signal-regulated kinase 1/2, cyclin D1/2, and vascular endothelial growth factor was markedly elevated in U251 O. The hyperproliferative and signaling effects seen in U251 O cells are abolished by selective CYP4A inhibition of 20-HETE formation with HET0016 [N-hydroxy-N′-(4-butyl-2-methylphenyl)-formamidine] , by small interfering RNA against the enzyme, and by the putative 20-HETE antagonist, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid. In vivo, implantation of U251O cells in the brain of nude rats resulted in a ∼10-fold larger tumor volume (10 days postimplantation) compared with animals receiving mock-transfected U251 cells. These data show that elevations in 20-HETE synthesis in U251 cells lead to an increased growth both in vitro and in vivo. This suggests that 20-HETE may have proto-oncogenic properties in U251 human gliomas. Further studies are needed to determine whether 20-HETE plays a role promoting growth of some human gliomas.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 10-19 (10 pages)

Journal (Volume, Issue Number)

Journal of Pharmacology and Experimental Therapeutics (Volume 327, Issue 1)

Publication milestones

  • Published - 10/2008

Publication status

Published - 10/2008

ISSN

0022-3565

Publication IDs

  • Scopus: 52649173364
  • PubMed: 18591218

Publication metrics

Metrics

SciVal
FWCI
1.05
SciVal
Author count
9
SciVal
citations
36
SciVal
Paper percentile
84
Scopus
citations
Fractional count
1
Fractional count
0.11
Fractional count
8
Fractional count
0.89
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
41
Captures
31

Funding Details

FunderFunding number
NINDS
K08NS045077